Key points from article :
"The lipidomic risk, derived from single mass spectrometric measurement is cheap, fast, informative and could extend traditional risk assessment based on clinical assays,” wrote Chris Lauber and colleagues.
Lipidomics measured different types of fat present in the blood, to assess future type 2 diabetes and CVD risk in 4,067 patients in Sweden.
In the incidence of CVD and type 2 diabetes during a 23-year follow-up, the researchers used 184 plasma lipid concentrations.
They measured lipids at baseline to establish a lipidomic incidence risk score for type 2 diabetes and CVD.
168% and 84% increase in the incidence of type 2 diabetes and CVD, respectively were reported.
"A subset of individuals at high risk for developing type 2 diabetes or CVD can be identified years before disease incidence".
"Future clinical lipidomics test facilitates physicians to intervene much earlier potentially preventing disease onset".
"Lipidomics is used to develop new therapies and medications and, find new biomarkers," said first author Lauber.
A study by TWINCORE Center for Experimental and Clinical Infectious Research, in Germany, published in PLOS Biology.
